Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin administration in ICU patients with COVID-19 and hypoalbuminemia
IRCT20221011056144N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of albumin (human) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Mortality rate, Lung involvement rate and 1 more. Started Dec 2022; status: completed.
02
Drugs
albumin (human)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20221011056144N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221011056144N1.